Retrophin Inc - Company & Market Research Reports

Retrophin is a biopharmaceutical company that is based in San Diego, California. The company’s leading pipeline assets are fosmetpantotenate (RE-024), is a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease. Its marketed products include Chenodal, Cholbam and Thiola. Retrophin was founded in 2011.

From
From
From
From
Glomerulonephritis - Pipeline Review, H2 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 212 Pages
From
From
Glomerulonephritis - Pipeline Review, H1 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 201 Pages
From
Glomerulonephritis - Pipeline Insights, 2018 - Product Thumbnail Image

Glomerulonephritis - Pipeline Insights, 2018

  • Drug Pipelines
  • 102 Pages
From
From
From
From
From
From
Loading Indicator
adroll